Abstract
The increasing knowledge regarding breast cancer carcinogenesis has provided possible opportunities to prevent breast cancer. This paper reviews the issues related to breast cancer chemoprevention including the identification of high-risk groups, biomarkers and potential chemopreventive agents. Trials with tamoxifen have clearly shown that the risk of developing estrogen receptor (ER)-positive breast cancer can be reduced at the later stage of this malignancy. However, there was no beneficial effect on ER-negative cancers. The challenge is to find new agents, which achieve same or better efficacy but with fewer side effects. Raloxifene has similar efficacy to tamoxifen, but leads to more favorable histologic profiles of endometrial tumors and fewer gynecologic symptoms and thrombo-embolic events. Adjuvant trials for contralateral tumors suggest that aromatase inhibitors may be able to prevent up to 70-80% of ER-positive breast cancers. This is currently being investigated in two large prevention trials, the IBIS-II trial using anastrozole and the MAP.3 trial using exemestane. We therefore need to discover novel agents for ER-negative breast cancer.
Keywords: Breast cancer, chemoprevention, prevention trials, tamoxifen, aromatase inhibitors, SERMs
Current Enzyme Inhibition
Title: Breast Cancer Chemoprevention: Current Perspectives
Volume: 5 Issue: 4
Author(s): Takeru Oyama, Yumiko Yasui and Takuji Tanaka
Affiliation:
Keywords: Breast cancer, chemoprevention, prevention trials, tamoxifen, aromatase inhibitors, SERMs
Abstract: The increasing knowledge regarding breast cancer carcinogenesis has provided possible opportunities to prevent breast cancer. This paper reviews the issues related to breast cancer chemoprevention including the identification of high-risk groups, biomarkers and potential chemopreventive agents. Trials with tamoxifen have clearly shown that the risk of developing estrogen receptor (ER)-positive breast cancer can be reduced at the later stage of this malignancy. However, there was no beneficial effect on ER-negative cancers. The challenge is to find new agents, which achieve same or better efficacy but with fewer side effects. Raloxifene has similar efficacy to tamoxifen, but leads to more favorable histologic profiles of endometrial tumors and fewer gynecologic symptoms and thrombo-embolic events. Adjuvant trials for contralateral tumors suggest that aromatase inhibitors may be able to prevent up to 70-80% of ER-positive breast cancers. This is currently being investigated in two large prevention trials, the IBIS-II trial using anastrozole and the MAP.3 trial using exemestane. We therefore need to discover novel agents for ER-negative breast cancer.
Export Options
About this article
Cite this article as:
Oyama Takeru, Yasui Yumiko and Tanaka Takuji, Breast Cancer Chemoprevention: Current Perspectives, Current Enzyme Inhibition 2009; 5 (4) . https://dx.doi.org/10.2174/157340809789630271
DOI https://dx.doi.org/10.2174/157340809789630271 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Cell Reprogramming: Stem Cell Differentiation Stage Factors and An Agent Based Model to Optimize Cancer Treatment
Current Pharmaceutical Biotechnology Microwave-Assisted Synthesis of Benzo-fused Seven-membered Azaheterocycles
Mini-Reviews in Organic Chemistry Current Pathogenesis of Alzheimer’s Disease and Plants Derived Neuroprotective Phytoconstituents: A Comprehensive Review
Current Psychopharmacology Estrogen Receptors as Therapeutic Targets in Breast Cancer
Current Topics in Medicinal Chemistry Discrimination of Thermophilic and Mesophilic Proteins Using Support Vector Machine and Decision Tree
Current Proteomics Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Altered Hyaluronan Biosynthesis and Cancer Progression: an Immunological Perspective
Mini-Reviews in Medicinal Chemistry Comprehensive Analysis of Key Proteins Involved in Radioresistance of Prostate Cancer by Integrating Protein-protein Interaction Networks
Current Bioinformatics ras Genes and Human Cancer: Different Implications and Different Roles
Current Genomics Therapeutic Potential of Inhibiting Brutons Tyrosine Kinase, (BTK)
Current Pharmaceutical Design Ontologies of Drug Discovery and Design for Neurology, Cardiology and Oncology
Current Pharmaceutical Design Immunosuppressive Treatments in Acute Myocardial Infarction and Stroke
Current Pharmaceutical Biotechnology Recognition Sites for Cancer-targeting Drug Delivery Systems
Current Drug Metabolism Pharmacophore Based 3D-QSAR Study of Biphenyl Derivatives as Nonsteroidal Aromatase Inhibitors in JEG-3 Cell Lines
Medicinal Chemistry Role of Phase II Drug Metabolizing Enzymes in Cancer Chemoprevention
Current Drug Metabolism Withdrawal Notice: Computational Druglikeness Assessment, Synthesis, Characterization and In vitro Biological Activity Evaluation of some Novel Mixed Metal Complexes of 2-(butan-2-ylidene) Hydrazinecarbothioamide
Combinatorial Chemistry & High Throughput Screening Radiolabeled Nanoparticles, Angionesis and Therapeutics of Cancer Researches Together With Preclinical Models
Current Radiopharmaceuticals Systemic Drug Delivery Systems for Bone Tissue Regeneration– A Mini Review
Current Pharmaceutical Design Phytoconstituents of <i>Lantana camara</i> L.: Rekindling Hope in the Cancer Treatment
Current Bioactive Compounds Can Probiotics Cure Inflammatory Bowel Diseases?
Current Pharmaceutical Design